Novo Nordisk's battered stock enjoyed a moment of reprieve after Hims & Hers abandoned plans to launch a compounded version of the just-launched Wegovy pill. Shares in the Danish pharma group were up ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's rival oral formulation of semaglutide in a head-to-head diabetes trial, but likely won't answer the question of which ...